Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1

Conditions

Rhabdomyosarcoma 1Lung Neoplasms 1

Interventions

pembrolizumab 379Carboplatin 279Specimen Handling 266Nivolumab 256Magnetic Resonance Spectroscopy 245Cyclophosphamide 242Cisplatin 217Paclitaxel 207Radiotherapy 196Biopsy 171Gemcitabine 158Dexamethasone 149durvalumab 147atezolizumab 128Rituximab 123Doxorubicin 117Bevacizumab 115Ipilimumab 114Lenalidomide 113Radiation 111Pemetrexed 104Docetaxel 104Etoposide 102fludarabine 97venetoclax 96Capecitabine 94Radiosurgery 93Fluorouracil 93Oxaliplatin 91Prednisone 90

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × mocetinostat × 1 year × Clear all
NCT03220477 2025-08-06

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
28 enrolled
Thoracic

Lung Neoplasms

NCT04299113 2025-06-26

Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
38 enrolled
Sarcoma

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡